🇺🇸 FDA
Pipeline program

Imsidolimab

ANB019-209

Phase 2 small_molecule completed

Quick answer

Imsidolimab for Acne Vulgaris is a Phase 2 program (small_molecule) at Vanda Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Vanda Pharmaceuticals
Indication
Acne Vulgaris
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials